This is the authors' abstract. We don't add key points for this paper.
Background: Spondyloarthritis associated with Inflammatory Bowel Diseases (SpA-IBD) are immune-mediated diseases classified in the group of Spondyloarthritis (SpAs) and, concordantly, the association of joint and gut inflammation supports a tailored multidisciplinary approach. Objectives: In this study, we describe the distinctive clinical features of a large SpA-IBD patients' cohort and assess the therapeutic strategies used in integrative clinical real-world management, focusing on their effectiveness over a long period of clinical observation. Methods: Consecutive patients affected by IBD (Crohn's Disease or Ulcerative Colitis), were screened [1], referred to our Spondyloarthritis Clinic and, if diagnosed as SpA-IBD, enrolled in the SPIB Cohort (SPondyloarthritis in Inflammatory Bowel disease) [2]. The cohort underwent comprehensive gastroenterological and rheumatological assessments at baseline, 3, 6, and every 12 months [2]for 4 years. Extensive clinical data, and rheumatological and gastroenterological disease activity scores, were collected at each evaluation (Table 1), guiding a gastro-rheumatological approach towards an appropriate treatment strategies. Results: Since October 2016, 159 consecutive patients (mean age 49.1±13.6 years, 59% females) were diagnosed with SpA-IBD, 89 (56.0%) with axial involvement (axSpA-IBD) and 70 (44.0%) with peripheral involvement (pSpA-IBD). The female gender was significantly more represented in pSpA-IBD than in axSpA-IBD (p<0.032), and the duration of musculoskeletal symptoms was higher in axSpA-IBD than in pSpA-IBD (p<0.004) (Table 1). At baseline, patients reported high disease activity across all domains and relevant impairment in physical functioning and quality of life. Thirty-seven (23.3%) patients were assuming steroids (mean prednisone equivalent dose – PED: 7.81±8.31 mg) and 106 (66.7%) csDMARDs; 60 (37.7%) patients were already treated with b/tsDMARDs: 56/60 (93.3%) TNFi, and 4/60 (6.7%) Vedolizumab. Following the integrated gastro-rheumatological assessment, therapy with b/tsDMARDs was started in 46 patients more (+28.9%), accounting for a total number of 106 patients treated with: TNFi in 96/106 (90.6%), anti-IL-12/23 in 2/106 (1.9%), JAKi in 4/106 (3.8%), and Vedolizumab in 4/106 (3.8%). Therapy with oral steroids and/or csDMARDs was maintained in 27 (17.0%; mean PED 1.23±4.01) and 109 (68.8%) patients, respectively (Figure 1B). From 12 to 24-month follow-up, b/tsDMARDs were prescribed in 74/98 (75.5%) patients as follows: 91.9% TNFi, 2.7% anti-IL-12/23, 2.7% JAKi, 2.7% Vedolizumab, whereas therapy with oral steroids and csDMARDs was maintained in 10 (10.2%; mean PED 0.39±1.36) and 75 (76.5%) patients, respectively (Figure 1B). Subsequently, at the 36-month follow-up, therapy b/tsDMARDs was maintained in a similar percentage of patients (45/56, 80.4%), with an increase of anti-IL-12/23 (8.9%), JAKi (2.2%), and Vedolizumab (4.4%), and this therapeutic trend was substantially maintained until the 48-month follow up (Figure 1B). Therapy with oral corticosteroids and/or csDMARDs was continued, but at a lower dose, in a similar percentage of patients from the 36 to 48-month follow-up (Figure 1B). From baseline to month 48, the integrative gastro-rheumatologic management resulted in a significant improvement in all disease activity scores (except the pMayo score), along with a significant improvement in physical functioning and quality of life (Figure 1A). Conclusion: The SPIB Cohort is a representative and large cohort of SpA-IBD patients, characterized by a long-time clinical follow-up through integrated gastro-rheumatologic management. Our study demonstrates that thigh cooperation between rheumatologists and gastroenterologists enables a comprehensive assessment with the development of tailored and effective therapeutic strategies. REFERENCES: [1] Benfaremo D al. J Rheumatol 2021;48:179-187. [2] Luchetti MM et al. Eur J Intern Med 2019;64:76-84. Acknowledgements: NIL. Disclosure of Interests: Giulia Marchionni: None declared, Valentino Paci: None declared, Lucia Perini: None declared, Alen Zabotti: None declared, Alice Agostinelli: None declared, Ilaria Cimaroli: None declared, Raffaella Sordillo: None declared, Federico Fiorini: None declared, Raissa Di Zio: None declared, Emanuele Bendia: None declared, Antonio Benedetti: None declared, Devis Benfaremo: None declared, Michele Maria Luchetti AbbVie, Amgen, Eli Lilly, Janssen, Novartis and Pfizer., AbbVie, Janssen, Novartis and Pfizer, Abbvie, Gianluca Moroncini AbbVie, Janssen, Novartis and Pfizer, AbbVie, Janssen and Pfizer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Marchionni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: